DCs, in particular, are necessary mediators for inciting Type-I-prone CD8+ T cells, and DC vaccines represent a valid immunotherapeutic strategy to direct/amplify antigen-specific immunity against tumor blood vessels (8). This evidence concerns the gene CD8A and neoplasm.